Cargando…

Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease

BACKGROUND: Screening tests have been used for cognitive deficits in Parkinson's disease (PD). OBJECTIVE: This study compared the Montreal Cognitive Assessment (MoCA) test, the Mini-Mental State Examination (MMSE) and the clock drawing test for this purpose. METHODS: A total of 50 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Camargo, Carlos Henrique Ferreira, Tolentino, Eduardo de Souza, Bronzini, Augusto, Ladeira, Marcelo de Araújo, Lima, Ronilson, Schultz-Pereira, Gustavo Leopold, Young-Blood, Marcelo Rezende
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação de Neurologia Cognitiva e do Comportamento 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619276/
https://www.ncbi.nlm.nih.gov/pubmed/29213480
http://dx.doi.org/10.1590/s1980-5764-2016dn1004015
_version_ 1783267366307627008
author Camargo, Carlos Henrique Ferreira
Tolentino, Eduardo de Souza
Bronzini, Augusto
Ladeira, Marcelo de Araújo
Lima, Ronilson
Schultz-Pereira, Gustavo Leopold
Young-Blood, Marcelo Rezende
author_facet Camargo, Carlos Henrique Ferreira
Tolentino, Eduardo de Souza
Bronzini, Augusto
Ladeira, Marcelo de Araújo
Lima, Ronilson
Schultz-Pereira, Gustavo Leopold
Young-Blood, Marcelo Rezende
author_sort Camargo, Carlos Henrique Ferreira
collection PubMed
description BACKGROUND: Screening tests have been used for cognitive deficits in Parkinson's disease (PD). OBJECTIVE: This study compared the Montreal Cognitive Assessment (MoCA) test, the Mini-Mental State Examination (MMSE) and the clock drawing test for this purpose. METHODS: A total of 50 patients with PD were selected, 41 (82%) were diagnosed with dementia by the criteria of the Movement Disorder Society. The test Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-Cog) was used as the gold standard in comparison with the screening tests. RESULTS: The MoCA test (AUC=0.906) had a sensitivity of 87.80% and specificity of 88.89%. When the MMSE was associated with the clock drawing test (AUC=0.936), it had a specificity of 66.67% and sensitivity of up to 97.56%. CONCLUSION: The study suggests that the MoCA test can be a good screening test in PD. However, MMSE associated with the clock drawing test may be more effective than the MoCA test.
format Online
Article
Text
id pubmed-5619276
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Associação de Neurologia Cognitiva e do Comportamento
record_format MEDLINE/PubMed
spelling pubmed-56192762017-12-06 Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease Camargo, Carlos Henrique Ferreira Tolentino, Eduardo de Souza Bronzini, Augusto Ladeira, Marcelo de Araújo Lima, Ronilson Schultz-Pereira, Gustavo Leopold Young-Blood, Marcelo Rezende Dement Neuropsychol Original Articles BACKGROUND: Screening tests have been used for cognitive deficits in Parkinson's disease (PD). OBJECTIVE: This study compared the Montreal Cognitive Assessment (MoCA) test, the Mini-Mental State Examination (MMSE) and the clock drawing test for this purpose. METHODS: A total of 50 patients with PD were selected, 41 (82%) were diagnosed with dementia by the criteria of the Movement Disorder Society. The test Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-Cog) was used as the gold standard in comparison with the screening tests. RESULTS: The MoCA test (AUC=0.906) had a sensitivity of 87.80% and specificity of 88.89%. When the MMSE was associated with the clock drawing test (AUC=0.936), it had a specificity of 66.67% and sensitivity of up to 97.56%. CONCLUSION: The study suggests that the MoCA test can be a good screening test in PD. However, MMSE associated with the clock drawing test may be more effective than the MoCA test. Associação de Neurologia Cognitiva e do Comportamento 2016 /pmc/articles/PMC5619276/ /pubmed/29213480 http://dx.doi.org/10.1590/s1980-5764-2016dn1004015 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Camargo, Carlos Henrique Ferreira
Tolentino, Eduardo de Souza
Bronzini, Augusto
Ladeira, Marcelo de Araújo
Lima, Ronilson
Schultz-Pereira, Gustavo Leopold
Young-Blood, Marcelo Rezende
Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease
title Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease
title_full Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease
title_fullStr Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease
title_full_unstemmed Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease
title_short Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease
title_sort comparison of the use of screening tools for evaluating cognitive impairment in patients with parkinson's disease
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619276/
https://www.ncbi.nlm.nih.gov/pubmed/29213480
http://dx.doi.org/10.1590/s1980-5764-2016dn1004015
work_keys_str_mv AT camargocarloshenriqueferreira comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease
AT tolentinoeduardodesouza comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease
AT bronziniaugusto comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease
AT ladeiramarcelodearaujo comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease
AT limaronilson comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease
AT schultzpereiragustavoleopold comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease
AT youngbloodmarcelorezende comparisonoftheuseofscreeningtoolsforevaluatingcognitiveimpairmentinpatientswithparkinsonsdisease